AN9025 is an oral small molecule pan-RAS(ON) inhibitor designed to address a broad range of RAS mutations across multiple tumor types. We expect to initiate the phase I clinical study in the first quarter of 2026.
AN9025 demonstrates superior potency compared to a clinical benchmark pan-RAS(ON) inhibitor sharing the same mechanism of action, driving potent and broad-spectrum anti-tumor activity in both in vitro and in vivo models.
AN9025 inhibits the viability of RAS-addicted cancer cell lines
Antitumor effects of AN9025 in KRAS-driven xenograft mice models
